Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Found 33 studies with search of: | "Lanreotide" |
Rank | Status | Study | ||||
---|---|---|---|---|---|---|
1 | Recruiting |
GH, IGF-I and Somatostatin Analogues in Hepatocellular Carcinoma
|
||||
2 | Not yet recruiting |
An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome
|
||||
3 | Recruiting |
Prevention of Lymphorrhea by Lanreotide in Axillary Dissection for Breast Cancer
|
||||
4 | Completed |
Lanreotide Autogel-120 mg as First-Line Treatment of Acromegaly
|
||||
5 | Completed |
Assessment of the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel
|
||||
6 | Recruiting |
Treatment of the Dumping Syndrome With Lanreotide Autogel®
|
||||
7 | Active, not recruiting |
Lanreotide as Treatment of Polycystic Livers
|
||||
8 | Withdrawn |
Study to Evaluate Patients With Acromegaly Treated With Lanreotide Autogel (Somatuline ATG)
|
||||
9 | Completed |
Comparable Effects of Lanreotide Autogel and Octreotide LAR on GH, IGF-I Levels and Patient Satisfaction
|
||||
10 | Active, not recruiting |
Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients
|
||||
11 | Completed |
Efficacy and Safety Study of Varying Doses of Lanreotide Autogel in Patients With Acromegaly
|
||||
12 | Completed |
Impact of Somatostatin Analogs vs. Surgery on Glucose Metabolism in Acromegaly
|
||||
13 | Completed |
Effect of 120mg Somatuline Autogel at Different Dose Intervals (28, 42 or 56 Days) in Patients With Acromegaly
|
||||
14 | Terminated |
Lanreotide (Somatuline Autogel) in Thyroid-Associated Ophthalmopathy Treatment
|
||||
15 | Recruiting |
Lanreotide as Primary Treatment for Acromegalic Patients With Pituitary Gland Macroadenoma
|
||||
16 | Completed |
Efficacy and Safety of Lanreotide Versus Placebo for Treatment of Patients With Digestive Fistulae
|
||||
17 | Completed |
Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LAR
|
||||
18 | Active, not recruiting |
Efficacy and Safety of Lanreotide Microparticles as Palliative Treatment in Peritoneal Carcinomatosis
|
||||
19 | Completed |
Efficacy and Safety of Lanreotide Autogel (60, 90 or 120 mg) in Acromegalic Patients
|
||||
20 | Recruiting |
Study of Lanreotide Autogel in Non-Functioning Entero-Pancreatic Endocrine Tumours
|
Previous Page | Studies Shown (1-20) | Next (21-33) |